CURIUM

📅 Upcoming

🕒 Recent(90d)

News

• Curium prices generic radioligand at 5% discount to Novartis' Lutathera
  Curium has set the list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion — about a 5% discount to the cost of the pharma giant’s drug. Challenging Novartis in th…
  endpoints · 22d ago
• 3 steps for taking on Novartis in radiopharma: Curium up first
  To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
  biospace · 1mo ago
• How radioligand therapy is rewriting cancer care
  In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Dev…
  biospace · 1mo ago
• FDA clears first generic radioligand drug; Sionna turns to layoffs
  A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
  biopharma_dive · 1mo ago
• FDA approves first radioligand generic, setting up rivalry with Novartis
  For the first time, Novartis’ leadership in the radioligand field will be tested by a generic rival. Curium announced on Monday that the FDA has approved its “radioligand equivalent” to Novartis’ L…
  endpoints · 1mo ago
• Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
  While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
  biospace · 2mo ago
• FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
  Lantheus, which recently agreed to an $8 billion takeover by fellow radiopharma Curium, garnered FDA clearance for its Alzheimer’s PET imaging agent Tauklarify.
  fiercebiotech · 2mo ago
• Curium buys radiopharma rival Lantheus for $8B; Sandoz settles price-fixing case
  ☢️ Curium spends $8B for Lantheus: Curium is buying fellow radiopharma company Lantheus for $102.5 per share. Lantheus shareholders may receive $12 more per share if certain targets are achieved ...
  endpoints · 2mo ago
• Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
  Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
  biospace · 2mo ago
• Curium strikes up to $8B deal for radiopharma rival Lantheus
  Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
  fiercebiotech · 2mo ago